Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

J&J says study found its investigational HIV vaccine didn’t provide enough protection

By Sean Whooley | August 31, 2021

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) today announced results from a trial of its HIV vaccine demonstrating a lack of sufficient protection against infection.

New Brunswick, N.J.–based Johnson & Johnson’s Imbokodo Phase 2b HIV vaccine clinical trial found that the investigational vaccine regimen did not provide sufficient protection against HIV infection in a 2,600-person population of young women in sub-Saharan Africa who are at high risk of acquiring HIV, although the vaccine was found to have a favorable safety profile with no serious adverse events.

The Imbokodo vaccine regimen was administered to participants through four vaccination visits over one year, with primary analysis conducted at 24 months following the first vaccination. The study found that 63 of 1,109 participants who received placebo, compared to 51 of 1,079 participants who received active vaccine, acquired HIV. The analysis demonstrated a vaccine efficacy point estimate of 25.2%.

Based on the results, the Imbokodo trial will not continue, with study participants set to be notified of the results, unblinded and informed as to whether they were in the vaccine group or placebo group within the study. Additional analysis of the Imbokodo study remains ongoing, with enough data available to progress with key immunological correlates research, J&J said in a news release.

In parallel to the Phase 2b Imbokodo HIV vaccine trial, J&J’s Janssen unit continues to sponsor the ongoing Phase 3 Mosaico study testing the safety and efficacy of a different composition of the HIV vaccine regimen among men who have sex with men (MSM) and transgender individuals. That company is conducting that study in the Americas and Europe where different strains of HIV are circulating.

“We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” J&J vice chairman of the executive committee & CSO Dr. Paul Stoffels said in the release. “HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system.

“While we are disappointed that the vaccine candidate did not provide a sufficient level of protection against HIV infection in the Imbokodo trial, the study will give us important scientific findings in the ongoing pursuit for a vaccine to prevent HIV. We continue to stand in solidarity with people living with and vulnerable to HIV, and remain committed to furthering our research against this devastating virus.”


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: HIV, HIV vaccine, Imbokodo, Johnson & Johnson
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50